Myofibrillar Myopathies and the Z-Disk Associated Proteins by Ruparelia, Avnika et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 14 
 
 
 
 
© 2012 Bryson-Richardson et al., licensee InTech. This is an open access chapter distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Myofibrillar Myopathies and  
the Z-Disk Associated Proteins 
Avnika Ruparelia, Raquel Vaz and Robert Bryson-Richardson 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/50110 
1. Introduction 
Myofibrillar myopathies (MFMs) are typically autosomal dominant myopathies with late 
onset progressive muscle weakness and symptoms initially evident in the distal muscle 
groups. However, there is a significant variability in the presentation of these diseases, with 
the age of onset ranging from infantile to late seventies; the involvement of the heart, 
respiratory muscles, distal or proximal muscle groups; and severity covering the full 
spectrum from mild muscle weakness to premature lethality. Several myopathies were 
identified with symptoms within this broad spectrum and the recognition of a common 
pathology allowed the grouping of these diseases under a single term, MFM [1]. Problems in 
the classification of these disorders still exist, partially due to the wide spectrum of clinical 
presentation and the lack of detailed analysis of biopsy samples to identify the defining 
features of MFM. 
The defining features of MFM, identified using histological stains and electron microscopy, 
are the dissolution of muscle fibres and the formation of protein aggregates. Common 
pathological features of MFM include presence of amorphous, granular, filamentous or 
hyaline deposits, interstitial fibrosis, fatty infiltration, centrally located nuclei indicative of 
regeneration, necrosis and muscle degeneration. Displaced membranous organelles are also 
evident, either in the cytoplasm or within autophagic vacuoles. Affected areas of the cells 
are frequently devoid of oxidative enzymatic activity and mitochondria can be abnormally 
shaped and positioned [2-5]. Characterization of the protein aggregates using 
immunohistochemistry reveals the presence of a wide range of sarcomeric, extracellular, 
and ubiquitously expressed proteins including Myotilin, Desmin, αB-Crystallin, Filamin C, 
BAG3, ZASP, Actin, Titin, Myosin, Xin, Dystrophin, sarcoglycans, Plectin, Delsolin, 
Ubiquitin, Neural cell adhesion modulator, Gelsolin, Syncoilin, Synemin, TAR DNA-
binding protein 43, Heat-shock protein 27, and DNAJB2 [6]. Interestingly, α-Actinin, which 
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is the primary Z-disk crosslinker and is associated with many of the Z-disk proteins 
mutated in MFM, is not detected in these protein aggregates [6,7]. 
The Z-disk provides an important structural linkage in the transmission of tension and 
contractile forces along the muscle fibre and has a role in sensing of muscle activity and 
signal transduction. In line with the identification of the Z-disk as the primary site affected 
in these myopathies the identification of MFM causing mutations has revealed a very strong 
association with the Z-disk, with all of the proteins affected being localised to this structure. 
Mutations have been identified in the intermediate filament (IF) protein Desmin [8], the 
chaperone αB-Crystallin [9], the structural protein Myotilin [10], the α-Actinin binding 
protein ZASP [11], the actin binding protein Filamin C [12], and the co-chaperone BAG3 
[13]. Based on the Mayo Clinic MFM cohort, 14% of MFMs are due to mutations in ZASP, 
13% due to Myotilin mutations, 8% Desmin mutations, 5% αB-Crystallin mutations, 4% 
BAG3 mutations, and 4% due to mutations in Filamin C, with the genetic basis of more than 
50% of MFM cases remaining unknown [14]. 
Whilst subtle differences in morphology and histochemical staining are found to be 
associated with certain MFM subtypes [3], they are not reliable in identifying the genetic 
cause of MFM. Ultrastructural studies on the other hand have been shown to be more 
informative in identifying the subtype of MFM, although repetition with large sample sizes 
is required to determine the reliability of ultrastructure studies is directing diagnosis [15]. 
Mutations in any of the identified MFM genes can also result in other forms of myopathy 
including dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), distal 
myopathy, spheroid body myopathy (SBM), and limb-girdle muscular dystrophy (LGMD). 
Whilst mutations can result in different myopathies, within the cases of MFM there is a 
remarkable consistency in the phenotype regardless of the gene mutated. This unifying 
pathological presentation suggests a common mechanism of pathology, although the 
functions of the MFM proteins and how their mutation results in disease are not fully 
understood. Determination of the mechanism by which these mutation result in disease will 
not only be important for the development of therapies for these conditions but will also 
provide insight into the role of these proteins in the muscle and the many functions of the Z-
disk. We present an analysis of the literature surrounding each of these proteins and how 
their mutations result in disease and discuss the implications for MFM and Z-disk function.  
2. Desmin and desminopathies 
Desmin, named from the word ‘desmos’ which means ‘link’ is a small, 53KDa, IF protein 
found in skeletal, smooth [16], and cardiac [17] muscle cells. In mature skeletal muscle, Desmin 
along with other Desmin-binding molecules such as Plectin, links adjacent myofibrils at the Z-
disk and binds them to the sarcolemma at the costameric level [18]. Desmin localisation to the 
intermediate filament, Z-disk, and costamere provides a cytoskeletal network that links the 
contractile apparatus to the cell membrane and other structural elements of the cell, which is 
critical for maintaining the integrity of the cell, ensuring force transmission and providing 
with a pathway for signalling. In order to form a fully functional IF network Desmin connects 
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with different cell structures from the cell membrane to the nuclear envelope. Therefore 
Desmin interacts with a range of different muscle, non-muscle, and nuclear proteins. At the Z-
disk, it interacts with αB-Crystallin (CRYAB) [19] and Nebulin [20,21]. At the periphery of the 
Z-disk, costameres, nucleus, and neuromuscular junctions Desmin interacts with Vimentin, 
Synemin [22], Paranemin [23], Desmulsin [24], Lamin [25], Plectin [26], Nestin [27], spectrins 
[28], and Ankyrin [29]. Deficiency in Desmin not only results in disturbance to the structure of 
the sarcomere, but also results in striking changes to the cellular morphology, which may have 
direct implications for muscle function. Desmin knockout mice show abnormal mitochondrial 
localization, accompanied by an increase in number and size, a rounded shape and distorted 
membranes, often showing granules and even mineralised bodies [30]. 
Structurally, Desmin is made up of three domains; an N-terminal head domain, a highly 
conserved central α-helical core, and a C-terminal tail domain (Figure 1). The central α-helical 
core, a region responsible for Desmin assembly into IF, is made up of four consecutive helical 
segments, 1A, 1B, 2A and 2B, which are linked by short non helical linkers [31,32]. These 
helical domains are made of tandem repeats of a specific seven amino acid sequence that 
contains the biochemical properties that allow the proper coiling of the protein. Additionally, 
the 2B helical domain contains a four amino acid insertion, known as the ‘stutter’, critical for 
Desmin assembly and conserved between many IF proteins [33,34]. Of the 50 Desmin 
mutations reported so far that result in severe skeletal and/or cardiac muscle defects the 
majority affect the coiled domains, five affect the head domain and eleven affect the tail 
domain (Figure 1). Interestingly, no mutations in domain 2A have been reported to date and 
more than 50% of reported Desmin mutations are in the 2B domain [35]. Although a 
correlation between the domain mutated and the clinical features of the patients/carriers has 
been suggested (reviewed in [35]), when the clinical features are analysed in more detail the 
only correlation that appears to be maintained is the predominance of skeletal muscle defects 
in patients with mutations in the 2B domain (Table 1 and Table 2). 
 
Figure 1. Schematic representation of Desmin domains and mutations. 
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Mutations are coloured accordingly to the disease classification. Note that 3’UTR is not 
drawn to scale. Mutations are coloured accordingly to the disease classification. Note that 
3’UTR is not drawn to scale. 
 
 
Mutation 
Age of 
onset / 
Initial 
symptoms
Clinical and pathological features; other studies Ref 
c.5G>T 
S2I 
? 
Skel 
Skel: MW. Pathology: abnormal myofibre size. Other studies: in vitro assembly 
assays showed assembly into a wider IF network; SW13 and MEF cells form a 
normal IF network. 
[36,37] 
c.137C>T 
S46F 
? 
Skel: MW. Pathological studies: abnormal myofibre size. Other studies: in vitro 
assembly assays showed IF assembly into wider filaments; SW13 cells form 
aggregates but MEF cells form a normal IF network. 
[36,37] 
c.137C>A 
S46Y 
? 
Skel: MW. Pathology: abnormal myofibre size. Other studies: in vitro assembly 
assays showed assembly into wider IF filaments; SW13 cells show aggregate 
formation but MEF cells form a normal IF network. 
[36,37] 
c.430A>T 
K144X 
37 
Card 
Card: DCM; AVB. [38] 
c.640-2A>C 
? (exon 3 
skipping) 
26-32 
Card 
Card: AVB that required pacemaker insertion. [38] 
c.1006G>T 
D336Y 
37 
Card 
Card: DCM; AVB; pacemaker insertion. [38] 
c.1315G>A 
E439D 
51 
Card 
Card: atrial fibrillation. [38] 
c.1325C>T 
T442I 
27-35 
Skel 
Skel: MW and wasting leading to wheelchair dependence; MA. Card: atrial 
fibrillation and arrhythmia that required pacemaker insertion; fatal heart failure in 
some cases. Pathology: fibre splitting; internally located nuclei; Desmin-positive 
aggregates and vacuoles in myofibres. Other studies: in vitro assembly studies 
showed normal IF; SW13 and C2C12 cells form normal IF network. 
[39] 
c.1346A>C 
K449Tx 
14 
Skel 
Skel: MW. Pathology: abnormal myofibre size. Other studies: in vitro assembly 
studies show normal filament formation; SW13 and C2C12 cells form normal IF 
network. 
[36,39] 
c.1360C>T 
R454W 
(+ Myotilin 
mutation) 
15 
Card 
Skel: slowly progressive MW. Card: HCM that required Card transplantation. 
Pathology: Desmin-positive aggregates within myofibres. Other studies: in vitro 
assembly studies showed formation of short and irregular filamentous structures 
and aggregates; SW13 cells show aggregate formation and C2C12 form normal IF. 
[39,40] 
c.1379G>T 
S460I 
29 
Card 
Skel: progressive MW and wasting. Card: AVB that required pacemaker 
implantation. Pathology: abnormal myofibre size; occasional split and regenerating 
fibres; vacuoles and Desmin-positive aggregates. Other studies: in vitro assembly 
studies showed normal filament formation; SW13 cells show aggregate formation 
but C2C12 form normal IF. 
[39] 
c.1413A>C 
X471Y 
35 
Card 
Card: AVB that required pacemaker implantation. [38] 
‘Other studies’ describes results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; 
MW: muscle weakness; MA: muscle atrophy; DCM: dilated cardiomyopathy; HCM: hypertrophic cardiomyopathy; 
AVB: atrioventricular block; SW13 cells: human carcinoma cells; MEF cells: mouse embryonic fibroblasts; C2C12 cells: 
mouse myoblast/satellite cells. 
Table 1. Description of clinical and pathological features of MFM caused by Desmin mutations. 
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Mutation Classification Ref 
c.38C>T S13F DRM [37,41-43] 
c.46C>T* R16C RCM [37,44] 
c.322G>A E108K DCM [45] 
c.338A_339Gdel Q113fsX115 DRM [46] 
c.517_537del* del(R173_179) DRM [47,48] 
c.638C>T (+α-glucosidase 
mutation) 
A213V DRM [49,50] 
c.639-1G>A + c.735+2A>G del(D214_E245) DRM [44,51-53] 
c.719dupA K240fsX243 distal myopathy [54] 
c.735G>C/T E245D distal myopathy [49,53,55] 
c.893C>T S298L DCM [45] 
c.934G>A D312N DCM [45] 
c.1009G>C A337P DCM [49,50,52,56,57] 
c.1013T>G L338R DRM [50] 
c.1024A>G N342D DRM [43,49,52] 
c.1034T>C L345P DRM [8,49,58,59] 
c.1049G>C R350P distal myopathy and CM [60] 
c.1048C>T R350W DCM [45] 
c.1064C>G E355P DRM [61] 
c.1069G>C A357P DRM [49,62] 
c.1075_1083del del(E359_S361) DRM [63] 
c.1078G>C* A360P DRM [49,52,56] 
c.1097_1099del del(N366) DRM [63,64] 
c.1099A>T I367F DRM [65] 
c.1109T>C L370P DRM [49,62,66] 
c.1130T>C L377P DRM [67] 
c.1154T>C L385P DRM [49,68] 
c.1166A>C Q389P DRM [49,69] 
c.1175T>C L392P DRM [65] 
c.1178A>T* N393I# DRM [49,50,52,56] 
c.1195G>T D399Y DRM [49,50] 
c.1201G>A E401K DRM [50] 
c.1216C>T R406W DRM [44,49,52,65,69,70] 
c.1237G>A E413K DRM [39,49,71] 
c.1255C>T P419S DRM [65] 
c.1353C>G I451M DRM [52,72-74] 
c.1358C>T T453I DRM [44] 
c.1375G>A V459I DCM [45] 
c.1405G>A V469M DCM [37,41-43] 
All disorders are dominantly inherited unless otherwise indicated.*: autosomal recessive inheritance; DRM: Desmin-
related myopathy; DCM: dilated cardiomyopathy; CM: cardiomyopathy; RCM restrictive cardiomyopathy. 
Table 2. Human myopathies caused by Desmin mutations excluding MFM. 
Mutations in Desmin result in many different myopathies (Table 1 and Table 2). Desmin-
related myopathies (DRM) is a term that has been used to describe myopathies due to 
mutations in Desmin and CRYAB including MFMs, here we only use it to refer to those 
caused by Desmin mutations. In addition to the broad spectrum of DRM, Desmin mutations 
have also been classified as MFM, distal myopathy, DCM, and RCM (see Table 1 and Table 
2). Some of the DRMs may be examples of MFM but without further information it is not 
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possible to re-classify them as MFMs. There is significant cardiac involvement in many 
Desmin myopathies and in some cases individuals with the same mutation may initially 
present with cardiac or skeletal muscle symptoms suggesting there is significant phenotypic 
variability and the possibility of modifiers of the Desmin myopathies. For example, the 
I451M mutation has been reported in a case of familial DCM without skeletal muscle 
phenotypes [72] and in individuals with skeletal myopathy without any evident cardiac 
defect [74]. Furthermore, the mutation was not fully penetrant in the family with DCM [72]. 
Potential modifiers include -Glucosidase, with a single individual identified as a 
compound heterozygote for -Glucosidase missense mutations and heterozygous for the 
Desmin A213V mutation displaying progressive muscle weakness not evident in related 
individuals carrying A213V alone [50], and Lamin A, as identified in an individual with 
Emery Dreifuss muscular dystrophy due to heterozygous Lamin A and Desmin V469M 
mutations [75]. 
Mutations in Desmin may also affect its capability to interact with its binding partners. 
Indeed, analysis of mutant protein E245D using solid phase binding assays showed that it 
binds to Nebulin with increased affinity, reducing Nebulin at the Z-disk, and is more prone 
to aggregate formation [76]. This interferes with Nebulin’s ability to regulate the thin 
filament and results in disease [76]. Furthermore, the targeted mutation K190A, not yet 
observed in disease, shows decreased affinity for Nebulin resulting in decreased targeting of 
Nebulin to the Z-disk, its accumulation in aggregates in both skeletal and cardiac muscle, 
and narrower Actin bundles. It was therefore hypothesised that the lack of functional 
Desmin prevents Nebulin from stabilising Actin thin filaments thereby resulting in collapse 
of the contractile apparatus [21]. 
To study the role of Desmin in muscle function two independent knockout mice lines were 
created [77,78]. Both lines develop normally, are viable and fertile, with no defects in 
myogenesis. However, they present postnatal multisystem disorder, decreased myofibril 
alignment, defects in nuclear and mitochondrial positioning within the cell, and severe 
cardiac degeneration [77-81]. Muscle of Desmin knockout mice was also found to be more 
susceptible to damage following contraction [82]. These studies show that the absence of 
Desmin does not impair muscle formation or animal viability however, it is important for 
muscle function and integrity. In addition to the abnormal localisation of mitochondria 
described in the knockout mouse [81], Desmin mutations, such as K240fsX243, R350P, and 
E413K, can result in abnormal localisation and function of the mitochondria resulting in a 
deficiency in oxygen metabolism which impairs muscle function and may contribute to 
muscle degeneration [49,54,71]. 
It has been extensively suggested that Desmin may be essential in lateral force transmission 
by connecting adjacent sarcomeres, and even neighbouring myofibres, by costamere-
extracellular matrix (ECM) binding. Therefore, Desmin mutations may impair its ability to 
respond to applied strain. Studies on Desmin with tail domain mutations in which the 
filament assembly is normal in both in vitro cell cultures and in transfected cells showed 
altered flexibility, with significantly increased stiffness compared to wildtype IF. This 
altered intrinsic properties of IF is hypothesised to prevent Desmin from responding to 
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excess strain thereby resulting in muscle pathology [40]. This is also supported by the 
del(Arg173-Glu179) knock-in mouse. Detailed analysis of the myocardium of these mice 
revealed the presence of aggregates containing Desmin and other muscle proteins, 
characteristic of desminopathies, which disturbed overall IF structure and compromised 
myocardium function both during baseline conditions and during maximal adrenergic 
stimulation [83]. 
The analysis of filament formation in vitro has identified a clear mechanism by which 
Desmin mutations may disrupt its assembly into filaments. However, it is still not clear 
which of the many roles of the IF contribute to pathology in desminopathies. The association 
of Z-disk proteins with MFM may suggest that it is the role of the IF at the Z-disk that is 
most relevant to these conditions but mitochondrial organisation and tethering of the 
myofibrils to the sarcolemma have clear links to muscle function and maintenance. The 
emerging application of whole genome and exome sequencing to mutation detection may 
improve identification of modifiers of pathology providing an alternative route to examine 
Desmin function, explain the phenotypic variations observed, and develop areas of potential 
therapy.  
3. B-crystallin and B-crystallinopathies 
To date 15 mutations in CRYAB have been reported. CRYAB belongs to the small Heat 
shock family of proteins (sHSP). It interacts with A-Crystallin (CRYAA) via non-covalent 
bonds to form large heterogeneous macromolecular complexes [19]. Both CRYAA and 
CRYAB are found in high levels in the lens tissue of the eye where they are involved in 
maintaining lens transparency and refractive index [84]. CRYAB is also found in significant 
amounts in non-lenticular tissues such as skeletal and cardiac muscle, the kidney, and the 
brain [85-87]. In skeletal muscle CRYAB expression is highest in the oxidative slow twitch 
muscle and lowest in the glycolytic fast muscle [85,88]. In skeletal and cardiac muscle 
CRYAB is localised to the Z-disk [89] where it interacts with the I-band protein Actin [19] 
and various IF proteins including Desmin [19], Vimentin [90], and Glial fibrillary acidic 
protein (GFAP) [91].  
The N-terminal globular domain and the highly conserved C-terminal ‘-crystallin domain’ 
(ACD; Figure 2) of CRYAB are critical for its chaperone-like function [92-94] and 
dimerisation [95]. CRYAB prevents stress induced aggregation of various proteins including 
β- and γ-Crystallins [93,93], Desmin [19], Vimentin [90], and GFAP [91]. Following stressful 
conditions such as osmotic stress, metal toxicity [96], serum starvation, hypertonic stress, 
and heat shock [90] CRYAB expression is up-regulated and recruited to the IF to remodel 
the IF network [90]. Mutations in CRYAB have been shown to interfere with both its 
dimerisation and chaperone functions. Resolution of the crystal structure of the MFM 
causing R120G mutant protein showed a disruption to its tertiary structure predicted to 
interfere with its dimerisation and result in the formation of large soluble oligomers [97]. 
Moreover, the ACD domain of mutant CRYAB adopts an irregular structure, which 
decreases its chaperone function, makes it unstable and promotes its aggregation [98-100]. 
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The mutant CRYAB has also been shown to have a higher dissociation constant, which 
prevents its dissociation from Desmin [101] resulting in Desmin containing aggregates as 
seen in MFM [100,101]. Therefore, alterations in the structure of CRYAB, its inability to 
perform its chaperone functions, and disruption of its interaction with its binding partners 
all contribute to disease pathology. In contrast to other MFM genes there does appear to be 
some correlation between genotype and phenotype with mutations in exon one resulting in 
isolated cataracts whilst exon three mutations can result in cataracts [102-107], MFM [108-
110], distal myopathy [111], and/or CM [112,113], with two mutations resulting in both 
cataract formation and muscle failure [114,115] (Table 3).  
Following contraction CRYAB is phosphorylated and translocates from the cytoplasm to the Z-
disk which is thought to allow CRYAB mediated repair or protection of the Z-disk [125]. 
Recently, a rare case of infantile onset MFM was identified due to a homozygous frameshift 
mutation, S115fsX14, resulting in muscle stiffness [110]. The authors suggest the mutation results 
in a loss of contraction timulated translocation to the Z-disk and consequent reduction in muscle 
repair. CRYAB has also been implicated in indirectly preventing apoptosis and autophagy, 
inhibiting Caspase 3 mediated [126], Ras induced[127], and Bcl-2 mediated apoptosis [128]. It is 
therefore not surprising that CRYAB deficiency results in decreased cell viability and an increase 
in apoptosis in CRYAB knock-out mouse [129] and in patients suffering with CRYAB mutations 
[108]. In basal breast cancer CRYAB behaves as an oncoprotein [130] and in highly migratory 
glioma cells prevents apoptosis [131] making it a potential target in cancer therapy. Up-
regulation of CRYAB may be part of a general protective mechanism since CRYAB is up-
regulated in various pathological conditions such as cardiac ischemia [132], multiple sclerosis 
[133], Alzheimer’s [134], and other neurodegenerative disorders [84]. 
Wildtype CRYAB has the capability to bind to mutant protein to prevent its aggregation. For 
example, transfection of the MFM causing R120G mutant CRYAB into PtK2 cells results in 
the formation of aggregates but co-transfection with wildtype CRYAB, or the chaperone 
molecule Hsp27, results in a significant decrease in the amount of insoluble R120G CRYAB 
present in the cell and the frequency of aggregate formation [135]. Recently the BAG3 co-
chaperone protein has also been shown to co-oligomerise with mutant CRYAB to suppress its 
aggregation and toxicity [136]. This does highlight that stimulating an increase in wildtype 
CRYAB, Hsp27, or BAG3 may be sufficient to prevent the formation of protein aggregates. 
The observation that there is a 10 fold increase in CRYAB expression in differentiating and 
proliferating myoblasts [137,138] suggests that CRYAB may play a role in regulating 
myogenesis. CRYAB has been shown to decrease the synthesis, and increase the 
degradation, of MyoD, a myogenic regulatory factor that specifies cell lineage, resulting in 
delayed differentiation. Additionally, up-regulation of CRYAB in muscle cells results in 
sustained expression of cell cycle markers such as Cyclin D1 indicating cells were more 
proliferative [139]. Therefore, CRYAB can influence myogenesis by altering MyoD levels 
and cell cycle exit. Despite the potential for CRYAB to regulate muscle differentiation 
CRYAB knockout mice have normal muscle at birth but present with severe muscular 
dystrophy by week 40 suggesting CRYAB is not critical for muscle development but is 
essential for muscle function [129]. 
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Mutation 
Age of 
onset / 
Initial 
symptoms 
Clinical and pathological features; other studies Ref. 
c.61delA* 
S21fcX44 
Birth-11 
weeks 
Resp 
Skel: hypertonia. Pathology: presence of necrotic and regenerating fibres; 
atrophic and splitting myofibres and internally located nuclei; Desmin-, 
Myotilin-, and some Ubiquitin-positive aggregates at the periphery of myofibres, 
vacuoles and deposits. Classified as MFM 
[9,109] 
c.325G>C 
D109H 
35-45 
Skel 
Skel: MW. Card: DCM; Cataract formation. Pathology: abnormal myofibre size; 
atrophic and splitting myofibres and internally located nuclei; Desmin-, CRYAB-, 
and Myotilin-positive aggregates and vacuoles. Classified as MFM 
[114] 
c.343delT* 
S115fsX14 
4 months 
Skel 
Skel: muscle stiffness. Pathology: muscle fibrosis. Classified as MFM [110] 
c.358A>G 
R120G 
? 
Skel 
Skel: MW; Card: HCM; Cataract formation. Pathology: presence of Desmin and 
CRYAB aggregates. Other studies: altered CRYAB quaternary structure; Partial 
unfolding exposes hydrophobic regions thus increases susceptibility to 
proteolysis and aggregation; disrupted protein binding; HeLa cells show 
hyperphosphorylation mutant CRYAB and accumulation in the cytoplasm; in 
vitro studies show Desmin and CRYAB aggregates in the cytoplasm and around 
the nuclei; rat cardiomyocytes with perinuclear aggregates containing Ubiquitin, 
β-Tubulin and Hsp25; cardiomyocytes in culture expressing mutant CRYAB 
show that the contractile apparatus does not work properly; mutant mice 
myofibrils alignment are impaired, CRYAB and in some cases Desmin- positive 
aggregates; cardiac hypertrophy; mitochondrial architecture and alignment are 
altered in cardiomyocytes; mice die by early adulthood. Classified as DRM 
[98,99,
115-
122] 
c.451C>T 
Q151X 
43 
Skel 
Skel: slowly progressive MW and MA. Pathology: severe abnormal myofibre 
size; necrotic and regenerating myofibres and internally located nuclei; abnormal 
Z-disks were detected; Desmin-, CRYAB- and Dystrophin-positive aggregates. 
Other studies: in vitro assays show that this mutation prevents oligomerisation, 
without changing its function, but aggregation is enhanced; in vitro assembly 
assays and COS-7 cells and cardiomyocytes cultures showed an increased 
tendency to hyperphosphorylation and aggregate formation. Classified as MFM 
[108,12
3,124] 
c.460G>A 
G154S 
48-68 
Skel or Card
Skel: slowly progressive MW and MA Card: DCM; moderate VEFR. Pathology: 
Desmin- and CRYAB-positive aggregates in subsarcolema and in the centre of 
the myofibres; Z-disk disorganization and smearing, with accumulation of 
vacuoles and other material. Classified as DCM 
[111,11
2] 
c.464CTdel 
L155fsX163 
52 
Resp 
Skel: MW. Pathology: abnormal myofibre size; fibre degeneration; presence of 
vacuolations and inclusions; disruption of the intermyofibrillar architecture; 
Desmin-, Myotilin- and CRYAB-positive aggregates. Classified as MFM 
[108] 
c.470G>A 
R157H 
40's 
Card 
Card: ventricular tachycardia. Other studies: rat cardiomyocytes show decreased 
CRYAB binding to Titin in the cardiac specific domain, without affecting its 
distribution in the cell. Classified as DCM 
[113] 
 
‘Other studies’ describes results from animal models and in vitro systems. Mutations involved in isolated cataract 
formation: R11H; P20S; R56W; D140N; K150fsX184 and A171T are not shown. All disorders are dominantly inherited 
unless otherwise indicated. *: autosomal recessive inheritance; Skel: skeletal muscle; Card: cardiac muscle; Resp: 
respiratory system muscles; MW: muscle weakness; MA: muscle atrophy; DCM: dilated cardiomyopathy; HCM: 
hypertrophic cardiomyopathy; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy; HeLa cells: 
human cervical cancer immortalised cells; COS-7 cells: African green monkey fibroblast. 
 
Table 3. Description of clinical and pathological features of B-crystallinopathies. 
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Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 2. Schematic representation of CRYAB protein structure and myopathy mutations. 
4. Myotilin and myotilinopathies 
The first description of myotilinopathy was a missense mutation in a family with LGMD1A 
[10]. Since this initial discovery, nine additional mutations in Myotilin (myofibrillar protein 
with Titin-like immunoglobulin domains) have been implicated in LGMD1A [10,140-142], 
MFM [143], SBM [144] or late onset distal myopathy [145] with all mutations described to 
date displaying an autosomal dominant pattern of inheritance. One of the mutations 
identified, S55F, has been found as a cause of both LGMD [141] and MFM [143] suggesting 
there may be modifiers of the disease that determine the symptoms produced or that there is 
an overlap in the classification of these conditions that needs to be resolved. Distinctions 
between these conditions are not clear, since the presence of protein aggregates is associated 
with MFM and SBM with weakness of distal muscle groups thought to be associated with 
MFM [143] and proximal muscle groups with LGMD (Table 4). 
Myotilin belongs to the immunoglobulin domain containing Actin binding protein family 
that also contains the Actin organizing proteins Palladin and Myopalladin [146,147]. 
Myotilin is predominantly expressed in skeletal and cardiac muscle, with the highest levels 
present in the skeletal muscle. Expression is also detectable at low levels in the peripheral 
nerves, bone marrow, liver, thyroid gland and lung [153,154]. In skeletal muscle Myotilin is 
present in both slow type I and fast type II fibers [151] and is localised to the Z-disk [153], 
although some reports have suggested Myotilin may also be found at the sarcolemma 
[10,153,155]. A role at the sarcolemma is also supported by the inclusion of Dystrophin in 
the protein aggregates found in MFM and LGMD1A [10,143]. Like many other Z-disk 
proteins Myotilin is very dynamic as demonstrated by fluorescent recovery after 
photobleaching (FRAP) experiments in quail skeletal muscle that showed that 80% of 
Myotilin in the Z-disk is replaced within five minutes of bleaching [156]. 
Myotilin contains two identified domains, both essential for its function; a serine rich N-
terminal domain, that shares no homology with any known protein, and a C-terminal domain 
consisting of two Ig-like domains that share high homology to two Z-disk associated Ig-like 
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domains of the giant protein Titin [153] (Figure 3). Seven of the eight identified Myotilin 
mutations, including the three MFM mutations [143], are in the serine rich domain with one 
mutation in the second Ig domain [142]. The serine rich domain consists of a stretch of 
hydrophobic residues that are believed to direct the localisation of Myotilin to the sarcolemma 
[10]. The serine rich domain is also responsible for the interaction of Myotilin with a range of 
proteins including the primary Z-disk crosslinker -Actinin [153], Filamin- Actin- and 
Telethonin-binding protein of the Z-disk (FATZ, Myozenin, Calsarcin) [157], ZASP/Cypher 
[158], Filamin C [157,159] and the ubiquitin ligases MURF-1 and MURF-2 [160]. Interaction of 
Myotilin with FATZ directly or indirectly directs the localisation of FATZ to the Z-disk [157]. 
Myotilin also links Filamin C, found at the periphery of the Z-disk, to -Actinin and anchors 
the Actin containing thin filaments to the Z-disk thereby providing stability to the sarcomere  
 
Mutation 
Age of 
onset / 
Initial 
symptoms
Clinical and pathological features; other studies Ref 
c.17G>A 
R6H 
40 
Skel 
Skel: progressive MW, culminated in wheelchair dependence. Pathology: 
abnormal myofibre size and fibrosis; necrotic fibres with macrophage invasion; 
internally located nuclei; mitochondria aggregation. Classified as LGMD1A 
[140] 
c.116C>T 
S39F 
Childhood-
60s 
Skel
Skel: progressive MW, in some cases wheelchair dependence.  Pathology: 
spheroid bodies with Myotilin immunoreactivity at the periphery. Classified 
as spheroid body myopathy 
[144] 
c.164C>T 
S55F 
48-53 
Skel 
Skel: slowly progressive to severe MW and wasting. Pathology: abnormal 
myofibre size with deposits and vacuoles; atrophic and necrotic myofibres; 
Myotilin-, CRYAB-, Dystrophin-, Desmin-. and Ubiquitin-positive aggregates; 
clusters of mitochondria. Classified as LGMD1A and MFM 
[141,143,1
48-150] 
c.170C>T 
T57I 
27 
Skel 
Skel: progressive MW. Pathology: abnormal myofibre size; myofibre 
degeneration and splitting; centrally located nuclei; vacuoles; Z-disc streaming. 
Other studies: mice reproduce human MFM pathology: Myotilin-, Desmin-, 
Ubiquitin-, and Actin-positive aggregates; fibrosis; Z-disk streaming and 
sarcomere disorganisation; some centrally located nuclei. Classified as 
LGMD1A 
[10,151] 
c.179C>G 
S60C 
50-77 
Skel 
Skel: severe MW and wasting. Card: some asymptomic cases; DCM; VEFR; 
sometimes fatal. Pathology: abnormal and atrophic myofibres with deposits 
and vacuoles; Myotilin-, CRYAB-, Dystrophin-, Desmin- and Ubiquitin- 
positive aggregates. Classified as MFM 
[143,148,1
52] 
c.179C>T 
S60F 
40-76
Skel 
Skel: difficulty in walking and climbing stairs; MW. Classified as distal 
myopathy 
[145] 
c.284G>T 
S95I 
? 
? 
Pathology: abnormal and atrophic myofibres with deposits and vacuoles; 
Myotilin-, CRYAB-, Dystrophin-, Desmin- and Ubiquitin- positive aggregates 
Classified as MFM 
[143] 
c.1214G>A 
R405K 
41 
Skel 
Skel: impossibility to walk long distances; MW. Pathology: abnormal myofibre 
size; scattered fibres with internally located nuclei; vacuoles and Myotilin-, 
ZASP-, Desmin- and Actin-positive aggregates. Classified as LGMD1A 
[142] 
c.1214G>A 
R405K 
41 
Skel 
Skel: impossibility to walk long distances; MW. Pathology: abnormal myofibre 
size; scattered fibres with internally located nuclei; vacuoles and Myotilin-, 
ZASP-, Desmin- and Actin-positive aggregates. Classified as LGMD1A 
[140] 
K36E and Q74K mutations are not shown since no information is available (shown in [142]). ‘Other studies’ describes 
results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; MW: muscle weakness; 
DCM: dilated cardiomyopathy; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy. 
Table 4. Description of clinical and pathological features of myotilinopathies. 
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[159,161]. The Ig domain containing C-terminus on the other hand is responsible for 
antiparallel dimerization of Myotilin, which is essential for its function [153,161]. The 
Myotilin C-terminus also interacts directly with Actin, despite the lack of a conventional 
Actin binding site [162], and is thought to prevent the depolymerisation of Actin filaments 
and enhance the binding of -Actinin to Actin. Overexpression of Myotilin in CHO cells 
results in formation of Actin bundles and the delayed expression of Myotilin relative to 
other Z-disk proteins is thought to be required to avoid premature bundling of Actin fibres 
[161,162]. 
Despite the loss of muscle integrity in myotilinopathies Myotilin knockout mice display no 
muscle defects. Their Z-disk structure and sarcolemma integrity is maintained with no effect 
on muscle strength and the heart appears normal [163,164]. This suggests that other closely 
related proteins, such as Palladin and Myopalladin, may have overlapping functions to that 
of Myotilin and are able to compensate for its loss. Interestingly, mice deficient in Myotilin 
have a two fold increase in the expression of the muscle stretch sensor Telethonin, which 
may be responsible for sensing the lack of Myotilin and triggering appropriate signals to 
prevent muscle failure [163]. However, this hypothesis needs to be validated. 
Analysis of Myotilin levels in patients compared to control individuals failed to identify a 
reduction in protein level [10,142] with other studies reporting an increase in Myotilin in 
some patients [142,165]. This observation leads to the hypothesis that mutations in Myotilin 
affect its dimerisation or interaction with binding partners, resulting in pathology. This is 
certainly true in the case of the identified missense mutation affecting the second Ig 
domain of Myotilin (R405K) resulting in LGMD [142]. The R405K mutation prevents 
dimerisation disrupting α-Actinin binding and Actin tethering to the Z-disk. As a result, 
filament stability is lost, the Z-disk is destabilised, and protein aggregates are formed [142]. 
However, this is not true for the majority of Myotilin mutations, which are found in the 
serine rich N-terminal domain. In vitro experiments have shown that the S55F, T57I, S60C, 
and S95I, mutations have no effect on Actin bundling [162], and T57I also has no effect on 
the interaction with α-Actinin [10]. It has since been hypothesised that mutated Myotilin 
promotes intermolecular aggregation with other similar Ig domain containing sarcomeric 
proteins such as Palladin and Titin. The mutant Myotilin expressing transgenic mouse 
(T57I) that contains aggregates rich in Ig domain containing proteins [151] supports this 
hypothesis. Interestingly, although in humans the T57I mutation results in LGMD1A in 
which aggregates are absent, expression in mice results in formation of aggregates that are 
typical of MFM and SBM. This led to the authors suggesting that the variation in 
symptoms between MFM, SBM, and LGMD1A, such as protein aggregates, are due to 
modifying loci [151]. 
The formation of protein aggregates is a defining feature of MFM and SBM. Aggregate 
containing muscle from myotilinopathy patients contains increased levels of oxidative stress 
markers including glycation end products, nitric oxide synthase, superoxide dismutase, and 
mutant Ubiquitin [166,167]. Protein oxidation promotes protein aggregation and reduces 
proteolytic degradation. Another factor that may promote protein aggregation in 
myotilinopathies and other MFMs is the inability of cells to degrade misfolded proteins via 
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the non-lysosomal ubiquitin proteasome system (UPS) responsible for the degradation of 80-
90% of myofibrillar proteins [168]. UPS mediated degradation of mutant Myotilin is 
significantly slower than wildtype Myotilin and inhibition of Myotilin turnover results in 
aggregates similar to those seen in MFM [169]. 
 
Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 3. Schematic representation of Myotilin domains and myopathy mutations. 
5. ZASP and zaspopathies 
Z band alternatively spliced PDZ-containing protein (ZASP) [170], also known as LIM 
Domain Binding 3 (LDB3), Cypher [171], or Oracle [172] belongs to the PDZ-LIM family of 
proteins and similar to other members of the family, Enigma [173] and α-Actinin associated 
LIM protein (ALP) [174], localises to the Z-disk. More than 15 mutations in ZASP have been 
reported resulting in a range of myopathies including DCM [11,175], HCM [176], MFM 
[177], inclusion body myositis [178], and LVNCC [11,175,177] (Table 5). ZASP contains a 
PDZ domain, located at the N-terminus, and an internal ZASP/cypher-like motif (ZM) both 
capable of interacting with α-Actinin-2 [179-181]. Additionally, the PDZ domain interacts 
with Myotilin [158] and FATZ [182], which provides structural stability to the Z-disk. The C-
terminus contains three LIM domains, which act to recruit signalling proteins to the Z-disk. 
As its name suggests the ZASP mRNA is extensively spliced to result in multiple ZASP 
isoforms, a feature conserved in all species examined with four isoforms in worms [183], 12 
isoforms in flies [184-186], 13 in zebrafish [187], and six in mice and humans [11,188] (Figure 
4). In mice and humans the isoforms have been characterised according to their length and 
their expression in the heart or skeletal muscle. So far two short isoforms, (2c, 2s) that lack 
the LIM domains, and four long isoforms (1c, 1s, 3c and 3s), that contain all three LIM 
domains, have been characterised [11,170]. Isoforms containing exon four (1s, 2s and 3s) are 
restricted to cardiac muscle whereas isoforms lacking exon four are found in both cardiac 
and skeletal muscle [11]. Loss and gain of function experiments have highlighted specific 
roles for the short and long isoforms. Selective deletion of the short isoforms does not lead 
to any muscle defects however, loss of the long isoforms results in neonatal lethality in 28% 
of mice [189]. Surviving knockout mice display growth retardation and Z-disk abnormalities 
in cardiomyocytes leading to DCM in adulthood, demonstrating the requirement for the  
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Mutation 
Age of 
onset / 
Initial 
symptoms
Clinical and pathological features; other studies Ref 
c.163G>A* 
V55I 
?
Card
Card: LVNCC. Classified as LVNCC 
[175,1
91] 
c.349G>A 
D117N 
30-41 
Card 
Card: DCM; AVB; EFR; premature death in some cases. Other studies: C2C12 
show ZASP aggregates formation and abnormal Actin staining. Classified as 
LVNCC
[11] 
c.407C>T 
K136M 
16
Card
Card: DCM; VEFR. Classified as LVNCC [11] 
c.464G>A 
(mRNA) 
A147T 
44-59 
Skel 
Skel: progressive MW and MA. Card: some cases of VEFR. Pathology: atrophic, 
necrotic, and regenerating myofibres; fibre splitting and internally located nuclei; 
small vacuoles and Desmin-, Myotilin-, CRYAB-, and Dystrophin-positive 
aggregates; streaming and disintegration of the Z-disk; organelles in clusters. 
Classified as MFM 
[177] 
c.519C>T 
(mRNA) 
A165V 
39-59 
Skel 
Skel: progressive MW and MA. Pathology: atrophic, necrotic, and regenerating 
myofibres; fibre splitting and internally located nuclei; small vacuoles and Desmin-
, Myotilin-, CRYAB- and Dystrophin-positive aggregates; streaming and 
disintegration of the Z-disk; organelles in clusters. Classified as LVNCC 
[177,1
92] 
c.587C>T 
S196L 
7-73 (not 
accurate)
Card
Card: DCM or HCM; VEFR. Other studies: mice show left ventricular dilation; 
HCM, VEFR; mild focal fibrosis; sarcomere and Z-disk disorganisation. Classified 
as DCM
[11,17
6,193] 
c.638C>T 
T213I 
15 months
Card
Card: AVB; VEFR. Other studies: Reduced binding to PGM1 Classified as DCM 
and LVNCC
[11] 
c.827C>T 
(mRNA) 
R268C 
73 
Skel 
Skel: progressive MW. Pathology: atrophic, necrotic, and regenerating myofibres; 
fibre splitting and internally located nuclei; small vacuoles and Desmin-, Myotilin-, 
CRYAB-, and Dystrophin-positive aggregates; streaming and disintegration of the 
Z-disk; organelles in clusters. Classified as MFM 
[177] 
c.1056C>G  
I352M 
<15-35
Card
Card: DCM; VEFR. Other studies: Reduced binding to PGM1. Classified as DCM [11] 
? 
D366N 
68
Card
Card: HCM. Classified as HCM [176] 
? 
Y468S 
(+CRSP3 
mutation) 
46 
Card 
Card: HCM. Classified as MFM 
[176,1
91] 
? 
Q519P 
21
Card
Card: HCM. Classified as HCM 
[176,1
91] 
c.1719G>A 
V566M 
40
Skel
Skel: slowly progressive MW; MA. Pathology: abnormal myofibre size; vacuoles 
and Desmin-, Myotilin-, CRYAB- and Ubiquitin-positive aggregates 
[178] 
? 
P615L 
28
Card
Card: HCM. Classified as HCM [176] 
c.1876G>A 
D626N 
after birth-
69 
Card
Card: DCM; LVNC. Other studies: mice show that mutant ZASP has higher 
affinity to PKC, which may cause the heart failure. Classified as LVNCC and 
DCM
[175,1
91] 
All conditions are dominantly inherited unless otherwise indicated. ‘Other studies’ describes results from animal 
models and in vitro systems. *: autosomal recessive inheritance; Skel: Skeletal muscle; Card: cardiac muscle; LVNCC: 
left ventricular non compaction cardiomyopathy; DCM: dilated cardiomyopathy; HCM: hypertrophic 
cardiomyopathy; AVB: atrioventricular block; VEFR: ventricular ejection fraction reduction; MW: muscle weakness; 
MA: muscle atrophy; MFM: myofibrillar myopathy; C2C12 cells: mouse myoblast/satellite cells 
Table 5. Description of clinical and pathological features of zaspopathies.  
long, but not the short, isoforms in maintaining Z-disk integrity [189]. Loss of both short and long 
isoforms however, results in death within the first five days [190] suggesting that there is some 
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redundancy in their roles. This hypothesis is supported by rescue experiments showing that 
expression of either the short or long skeletal isoform in ZASP deficient mice is sufficient for 
survival in 19% and 49% of carriers respectively [188]. The different phenotypes observed 
following loss of long or short isoforms raises the question whether mutations in specific 
isoforms result in specific myopathies. This is clearly true in the case of mutations in the cardiac 
specific exon four however, why mutations in exons expressed in both skeletal and cardiac 
muscle results in only one tissue getting affected is not clear. For example the D117N [11], 
A147W, and A165V [177] mutations in  exon six affect both skeletal and cardiac muscle isoforms. 
However, D117N preferentially affects the cardiomyocytes whereas A165V preferentially affects 
the skeletal muscle, and A147W results in both tissues being affected. Therefore, there appears to 
be no clear correlation between the exon affected and the phenotype presented by the patient. 
Examination of the diaphragm muscles, which are not active before birth, in ZASP knockout 
mice identified little or no difference in the sarcomere structure at E17.5 when compared with 
wildtype mice, but severe disruption of the Z-disk the day after birth [190], suggesting that 
ZASP is not required for sarcomere assembly but is critical for maintenance of Z-disk integrity. 
Examination of cardiac muscle in these mice, which becomes active at E8, at E17.5 identified 
severely disrupted Z- disks which were completely lost by one day after birth [190]. A role for 
ZASP in Z-disk maintenance is supported by experiments demonstrating that deletion of ZASP 
in postnatal hearts results in gradual disruption of the Z-disk and severe DCM resulting in 
premature death within five months [194]. Targeted deletion of ZASP homologues in Drosophila 
results in defects in muscle development suggesting a role for ZASP is in Drosophila 
sarcomerogenesis [184,185]. However, Drosophila has only a single protein equivalent to the 
mammalian ZASP, ALP, and Enigma proteins. It is therefore possible that in mammals, ZASP, 
ALP, and Enigma have redundant roles and loss of all three proteins in mammals would result 
in a phenotype similar to that seen in Drosophila. In Drosophila ZASP was identified as a 
regulator of cell matrix adhesion localising to integrin adhesion sites in S2 and S2R+ cell lines co-
localising with α-Actinin at the Z-disks and integrins at the myotendinous junctions in embryos 
[184]. ZASP deficient flies display a muscle detachment phenotype and lack α-Actinin at the Z-
disk, suggesting that the interaction of ZASP with Integrin is critical in connecting the muscle 
fibre to the ECM and in directing α–Actinin to the Z-disk [184]. However, localisation of ZASP 
to myotendinous junctions or costameres has not been reported in any other animal model. 
In cardiomyocytes ZASP interacts with Protein Kinase C (PKC) [175], a known modulator of 
cardiomyocyte growth and contractility. PKC-ε has been shown to interact with RACK-2 
and protect cardiomyocytes from ischemic stress [195,196]. Disruption of the PKC-ε - RACK-
2 complex results in inhibition of cell contraction [197] and accelerated cell death [198]. In 
vivo studies have revealed increased levels of PKC in hypertrophy, DCM, and heart failure 
[199-201], suggesting a role for PKC in stress response, potentially modulated by ZASP. 
Biochemical analysis of ZASP revealed that the D626N LIM domain mutation increases the 
binding affinity of ZASP for PKC. The authors suggest that this may reduce the amount of 
PKC-ε available to bind downstream proteins such as RACK-2 therefore resulting in DCM 
due to altered distribution of PKC [175]. ZASP also interacts with the metabolic protein 
Phosphoglucomutase 1 (PGM1), an enzyme involved in glycolysis and gluconeogenesis, 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 332 
through the proline rich regions encoded by exons four, six and, ten and recruits it to the Z-
disk [202]. DCM causing mutations in exon four (S196L and T213I) and exon ten (I352M) 
have been shown to have reduced binding affinity for PGM1 [202]. The binding of ZASP to 
PGM1 and ZASP mediated targeting of PGM1 to the Z-disk are both increased under stress 
condition further supporting a role of ZASP in protection and repair of the Z-disk, although 
the role of PGM1 at the Z-disk is not clear [202]. 
 
ZASP contains 16 exons, although no ZASP protein is coded by the hypothetical full-length cDNA. The hypothetical 
full-length protein is a representation of all protein domains and all mutations described in humans so far. Six splice 
forms have been described (1s, 1c, 2s, 2c, 3s, 3c) and named accordingly to the presence specific exons, such as the 
cardiac specific exon 4 (c for cardiac and s for skeletal). Each splice form is shown with all mutations present on the 
exons it contains accordingly to the amino acid change described when published. Therefore, numbering 
incongruences are detected depending on the splice form analysed. Mutations are coloured according to the disease 
classification. Note that the 3’UTR is not drawn to scale. 
Figure 4. Schematic representation of ZASP domains, human splice variants, and mutations. 
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6. Filamin and filaminopathies 
Filamin C (FLNC) was first implicated in MFM in 2005 with the identification of a missense 
mutation in a German family that presented with weakness of the proximal muscle groups 
and respiratory insufficiency [12]. Since this initial discovery five additional FLNC 
mutations have been identified of which two result in MFM [203,204] and three cause distal 
myopathies in which protein aggregates are not evident [205,206] (Table 6). 
 
Mutation 
Age of onset 
/ 
Initial 
symptoms
Clinical and pathological features; other studies Ref 
c.577G>A 
A193T 
30's 
Skel 
Skel: MW. Pathology: residual fibre size variation; focal increase in 
fibrosis and internal nuclei. Other studies: C2C12 show increased 
number of stress fibres and cell projections; FLNC- and Actin-positive 
aggregates were detected. Classified as distal myopathy 
[205] 
c.752T>C 
M251T 
30's 
Skel 
Skel: slowly progressive MW. Card: some developed CM. Pathology: 
abnormal myofibre size; internally located nuclei. Classified as distal 
myopathy 
[205] 
c.2695_2712del + 
GTTTGTins 
del(K899_V904) + 
ins(V899_C900) 
35-40 
Skel 
Skel: progressive MW. Card: AVB. Pathology: variation in myofibre size 
and increased numbers of internal nuclei; vacuoles and deposits positive 
for Desmin, Dysferlin, Dystrophin and Ubiquitin; necrotic and 
regenerating myofibres; nemaline bodies. Classified as MFM 
[204] 
c.2788_2799del 
del(V930_T933) 
34-60 
Skel 
Skel: difficulty to stand or walk; progressive MW. Pathology: abnormal 
myofibre size; atrophic myofibres and internally located nuclei; 
aggregates positive for FLNC, Ubiquitin, Desmin, Myotilin and CRYAB; 
nemaline bodies and mitochondria aggregates. Classified as MFM 
[203] 
c.5160delC 
F1720fsX633 
20-57 
Skel 
Skel: MW and MA. Card: few cases of CM and VEFR. Pathology: from 
slight myofibre size variation and rare fibre splitting and internally 
located nuclei to myofibrillar disorganisation, Z-disk streaming, presence 
of small rods and other deposits. Classified as distal myopathy 
[206] 
c.8130G>A 
W2710X 
24-49 
Skel 
Skel: slowly progressive MW; wheelchair dependence in some patients. 
Card: some patients with HCM, AVB and VEFR. Pathology: splitting and 
necrotic fibres; internally located nuclei; aggregates positive for FLNC, 
Desmin, Myotilin and Dystrophin and vacuoles; Z-disk streaming and 
nemaline-rod formation. Other studies: protein studies showed a 
decreased stability and dimerisation capacity of the mutant FLNC; PtK2 
cells form aggregates. Classified as MFM 
[4,12,20
7] 
‘Other studies’ describes results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; 
MW: muscle weakness; MA: muscle atrophy; CM: cardiomyopathy; HCM: hypertrophic cardiomyopathy; AVB: 
atrioventricular block; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy; C2C12 cells: mouse 
myoblast/satellite cells; PtK2 cells: Potorous tridactylis kidney cells. 
Table 6. Description of clinical and pathological features of filaminopathies. 
FLNC belongs to the Filamin family of proteins characterised by their ability to cross link 
Actin. Three Filamin isoforms have been identified all of which are encoded by different 
genes [208,209]: Filamin A (α-Filamin or Filamin 1) and Filamin B (β-Filamin), which are 
ubiquitously expressed, and FLNC (Filamin 2, γ-Filamin, Actin Binding Protein 280 (ABP-
280) or Actin Binding Protein Ligand (ABP-L)) [210-212], which is expressed specifically in 
striated and cardiac muscle [204,212]. In striated muscle, FLNC localises in two different 
pools: 97% of FLNC is contained within the Z-disk of the sarcomere and 3% is found in the 
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sarcolemmal membrane at the level of the costameres and myotendinous junctions [213]. In 
cardiac muscle FLNC is found in intercalated discs [213,214]. 
Filamin proteins contain two distinct functional regions (Figure 5). The N-terminal region, 
which contains two calpain homology domains that are responsible for interacting with 
Actin and promoting its polymerisation [215]. Two of the three distal myopathy causing 
FLNC mutations, in which protein aggregates are not evident, are found in this N-terminal 
region. This suggests that the presence of a functional N-terminal Actin binding domain in 
MFM causing FLNC mutant protein may be important in the formation of protein 
aggregates. The other four FLNC mutations are found in the semi-flexible rod domain, 
which contains 24 homologous Ig-like domains, each about 93 to 103 amino acids long [203]. 
The Ig-like domains act as an interface for the interaction of FLNC with its binding partners 
and allow FLNC dimerisation, through domain 24 [216], which is essential for its function.  
Disruption of FLNC dimerisation leads to failure of the Z-disk as in the case of W2710X 
MFM causing FLNC mutation. Truncation of the dimerisation domain results in the loss of 
secondary structure of the mutant protein hence making it less stable and more susceptible 
to degradation by proteolytic enzymes [12,207], but is also more prone to aggregation [207] . 
Although the mutant protein is unable to form dimers, it neither disturbs dimerisation of 
wildtype FLNC nor affects its interaction with Actin or the sarcoglycans, two key FLNC 
binding partners [207]. In between FLNC Ig-like domains 15 and 16 (Figure 5), a 
differentially spliced Hinge 1 (H1) region is present, that provides flexibility to FLNC, but is 
absent from the predominant form expressed in striated muscle. Additionally, FLNC has a 
second hinge region (H2, Figure 5) between Ig-like domains 23 and 24, found in both splice 
variants [210,212], and contains a unique 82 amino acid insert between Ig-like domains 19 
and 20 [213], which is thought to recruit FLNC specifically into the Z-disk [157]. 
 
Mutations are coloured according to the disease classification. 
Figure 5. Schematic representation of FLNC domains and mutations. 
FLNC has been proposed to have several functions in the muscle. The interaction of Ig-like 
domain 20 of FLNC with the Z-disk protein Xin is important in regulating the development 
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and remodelling of the Actin cytoskeleton [217]. Additionally, the interaction of FLNC Ig-
like domains 19, 20, 21, and domain 23 with the Z-disk proteins Myotilin [159] and FATZ 
[157,182,218,219] maintains the stability of the sarcomere. At the sarcolemma, FLNC 
interacts with the transmembrane proteins γ- and δ-Sarcoglycans (repeats 20 to 24) [213], 
Cbl-associated protein (CAP or Ponsin, domain 2) [220], Ankyrin G (repeat 5 and 6) [221], 
and β1-integrin (domain 20-21) [157]. FLNC therefore connects the Z-disk to the sarcolemma 
and the ECM providing both a structural linkage and a mechanism for signalling from the 
sarcolemma to the Z-disk [159,213]. In cardiac muscle FLNC interacts with Nebulette [222], 
the cardiac specific homologue of the thin filament ruler Nebulin. This interaction has been 
thought to be important in targeting FLNC to the cytoskeleton therefore ensuring the correct 
localisation and function of FLNC. FLNC, through Ig-like domains 20, 21, and 23 also 
interacts with the muscular dystrophy KY protein but the functional importance of this 
interaction is not known [214]. The identification of a distal myopathy as a result of FLNC 
haploinsufficiency suggests that the levels of FLNC maybe critical for its function [206]. 
Additionally, the altered distribution of both sarcomeric and ECM proteins in 
filaminopathies suggests that the functions of FLNC at the Z-disk and sarcolemma are 
compromised in filaminopathies. Analysis of the FLNC mouse knockout identified a 
decrease in the number of primary muscle fibres suggesting a role for FLNC in myogenesis 
[223]. However, the recent characterisation of a Medaka FLNC mutant showed no difference 
in the expression of myogenic factors [224]. The role of FLNC in fibre differentiation is 
therefore still questionable. 
The process by which mutations in FLNC result in muscle disease is not understood but the 
identification of a haploinsufficient form of filaminopathy, and the finding that the W2710X 
mutant does not disrupt wildtype FLNC dimerisation, together with the severe muscle 
defects seen in the FLNC knockout mouse suggest that Filamin related MFM manifests as 
result of direct or indirect loss of functional FLNC. It is therefore hypothesised that the 
progressive, late-onset, nature of filaminopathies results from a reduction in FLNC function 
commensurate with the increasing sequestration of wildtype FLNC and FLNC binding 
partners by mutant FLNC in the cytoplasm. 
7. BAG3 and bag3opathies 
Bcl2-related athanogene 3 (BAG3, Bis, CAIR) is the most recently identified MFM causing Z-
disk protein with the report of a missense mutation (P209L) in exon three resulting in MFM 
with cardiac complications [13]. Since then 10 additional Bag3 mutations have been reported 
of which nine result in DCM [225,226] and one in MFM [227] (Table 7). BAG3 is one of six 
members of the BAG family of proteins. It is a multidomain co-chaperone expressed at high 
levels in skeletal and cardiac muscle and found at lower levels in tissues such as neurons, 
adrenal gland, ovaries and testis [228,229]. In skeletal muscle BAG3 co-localises with 
Desmin and α-Actinin at the Z-disk [228]. An increase in BAG3 expression is detected 
following an increase in static strain [230], eccentric contraction [231], or nemaline myopathy 
[232] which suggests that BAG3 plays a role in repair and regeneration of skeletal muscle 
injuries caused by mechanical stress and disease. 
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Mutation 
Age of onset 
/ 
Initial 
symptoms 
Clinical and pathological features; other studies Ref 
c.211C>T 
R71W 
41-59 
Card 
Card: DCM; VEFR; heart transplantation required. Classified as DCM [225] 
c.268C>T 
R90X 
44 
Card 
Card: DCM; VEFR. Classified as DCM [225] 
c.326A>G 
H109R 
21 
Card 
Card: DCM; VEFR. Classified as DCM [225] 
c.367C>T 
R123X 
25-36 
Card 
Card: DCM in some cases; some cases with VEFR; some required heart 
transplantation. Classified as DCM 
[225] 
c.626C>T 
P209L 
5-13 
Skel and 
Card 
Skel: moderate to severe MW and MA; easy fatigability Card: Restrictive 
HCM; heart transplantation needed in some cases; early death in most cases. 
Pathology: abnormal myofibre size which larger fibres showed splitting or 
breakdown; necrotic and regenerating myofibres and internally located 
nuclei; abnormal fibres with ectopic staining for BAG3, CRYAB, Desmin, 
Myotilin, Dystrophin and Ubiquitin; presence of dense structures and 
aggregates of mitochondria; Z-disk streaming. Other studies: neonatal rat 
cardiomyocytes showed problems in cell fusion; COS-7 cells presented 
granules in their cytoplasm; C2C12 with reduced BAG3 protein levels show 
increased apoptosis. Classified as MFM 
[13,226,
228,240] 
c.625C>T + 
c.772C>T 
P209W + 
R258W 
6 
Skel 
Skel: progressed from clumsy walking into MW and decreased spine 
movement Card: restrictive HCM. Pathology: atrophic fibres; focal 
myofibrillar disorganisation and degeneration; sarcoplasmic accumulation of 
granulofilamentous material. Classified as MFM 
[227] 
c.652C>T 
R218W 
73 
Card 
Cardiac muscle: ventricular wall thickness; severe VEFR; ectopic atrial 
rhythm. Other studies: neonatal rat cariomyocyes presented abnormal Z-disk 
assembly (seen by Desmin and α-Actinin staining) and increased 
susceptibility to apoptosis. Classified as DCM 
[226] 
c.652Cdel 
R218fsX89 
47 
Card 
Card: DCM; VEFR; early death. Classified as DCM [225] 
c.784G>A 
A262T 
42-44 
Card 
Card: DCM; AVB; severe VEFR; required heart transplantation. Classified as 
DCM 
[225] 
c.1385T>C 
L462P 
27-34 
Card 
Card: ventricular wall thickness; VEFR; cardiac contraction defects. Other 
studies: neonatal rat cardiomyocytes presented abnormal Z-disk assembly 
and increased susceptibility to apoptosis. Classified as DCM 
[226] 
c.1430G>A 
A477H 
47-50 
Card 
Card: DCM; severe VEFR; pacemaker insertion. Classified as DCM [225] 
‘Other studies’ describes results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; 
MW: muscle weakness; MA: muscle atrophy; HCM: hypertrophic cardiomyopathy; DCM: dilated cardiomyopathy; 
VEFR: ventricular ejection fraction reduction; AVB: atrioventricular block; MFM: myofibrillar myopathy; COS-7 cells: 
African green monkey fibroblast; C2C12 cells: mouse myoblast/satellite cells. 
Table 7. Description of clinical and pathological features of bag3opathies. 
BAG3 has three recognisable functional domains (Figure 6); no mutations have been 
reported in the WW domain containing N-terminal region, which interacts with proline rich 
motifs of signal transduction proteins, or in the proline rich central region, which interacts 
with WW domains and Src3 homology (SH3) domains of signal transduction proteins such 
as Phospholipase C (PLCγ) [233].  
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Two mutations have however been reported in the evolutionary conserved C-terminal BAG 
domain that has a key role in the apoptotic and chaperone functions of BAG3 [234-236]. The 
BAG domain binds with high affinity to, and regulates, stress inducible Heat shock protein 
70 (Hsp70) [233-235,237] and the constitutively expressed Heat shock cognate protein 70 
(Hsc70) [237], that ensure   
correct protein folding and targeting of misfolded proteins for proteasomal degradation 
[238]. BAG3 competitively binds to the ATPase domain of these chaperone proteins and 
alters their chaperone properties thereby targeting chaperone associated proteins for 
proteasomal degradation [237,239]. In fact, BAG3 has recently been shown to form a stable 
complex with the small Heat shock protein HspB8 and stimulate macroautophagy [236], a 
process that is particularly important in Huntington disease where association of BAG3 with 
HspB8 promotes degradation of mutant Huntingtin [236,241]. In inclusion body myositis, 
macroautophagy plays a role in removing -amyloid aggregates [242] and it is possible that 
BAG3 also plays a role in this cellular response to protein aggregates in MFM. However, as 
the primary defect in MFM is the dissolution of muscle fibres beginning at the Z-disk 
preventing the formation of protein aggregates is unlikely to be sufficient to prevent muscle 
pathology. 
In B-crystallinopathies BAG3 suppresses protein aggregation and toxicity by preferentially 
binding mutant CRYAB, reducing its aggregation and increasing its solubility [136]. This 
demonstrates that BAG3 not only indirectly regulates protein folding and degradation but 
also has the potential to prevent misfolding and promote degradation of mutant proteins 
thereby preventing disease pathology. Interestingly, deletion of the BAG domain results in a 
similar inhibition of aggregation of mutant CRYAB. BAG3 may therefore function through a 
pathway that is independent of Hsp70/Hsc70 [136]. BAG3 synergistically interacts with Bcl-
2, via the BAG domain, to prevent Bax induced and FasL- 
Fas mediated apoptosis [239,243]. BAG3 levels are up-regulated in response to oxidative 
stress [244], heat shock, heavy metal exposure [245,246], or photoinjury in the retina [247] 
and increased levels of BAG3 in human epithelial cells has been show to result in decreased 
Bax or Fas mediated apoptosis demonstrating the critical adaptive role of BAG3 in response 
to cell stress. 
Immunohistochemistry on P209L mutant muscle biopsy samples revealed increased 
immunoreactivity in abnormal fibres for the chaperone molecules Hsp27 and CRYAB and 
the anti- apoptotic protein Bcl-2. This was accompanied by increased apoptosis suggesting 
that the P209L mutation interfered with the anti-apoptotic functions of BAG3 [13]. Non-
denaturing gel electrophoresis revealed faster migration of the mutant BAG3 complex than 
wildtype [13], suggesting that the loss of function may be due to reduced interaction with 
partner proteins, possibly Bcl-2, given that an increase in apoptosis is observed. This is 
supported by transfection of P209L mutant BAG3 into neonatal cardiomyocytes resulting in 
increased susceptibility to stress mediated apoptosis [226] and the observation that mice 
deficient in BAG3 also display increased apoptosis [228]. It has been shown that the down-
regulation of BAG3 enhances the apoptotic response to chemotherapy in lymphocytic 
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leukaemia cells making it a potential target for cancer therapies [248], and further 
demonstrating its anti-apoptotic role. 
Since the primary defect in BAG3opathies is the fragmentation of fibres it can be 
postulated that perhaps BAG3 has a role in muscle development or maintenance of 
muscle structure. BAG3 deficient mice are normal at birth but cease to gain weight at day 
12. Muscle histology revealed myofibril and Z-disk defects with no sarcolemma damage 
[228]. Taken together, this data suggests that BAG3 is not necessary for sarcomerogenesis 
but is critical for maintenance of fibre integrity. By the 25th day BAG3 deficient mice die as 
a result of intercostal muscle failure or pulmonary oedema that results in cardiac failure 
[228]. Targeted knockdown of BAG3 in zebrafish has also resulted in severe cardiac 
defects demonstrating a critical role of BAG3 in maintaining the structural integrity of 
cardiomyocytes [225]. A recent study has shown that BAG3 regulates myofibril stability 
by facilitating the interaction of Hsc70 with CapZ, a protein that caps the barbed ends of 
Actin filaments that extend into Z-disk [230]. Loss of BAG3 makes CapZ more vulnerable 
to degradation resulting in loss of CapZ and fibre fragmentation following mechanical 
stress [230]. 
 
Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 6. Schematic representation BAG3 domains and mutations. 
In summary, the most recently identified MFM causing gene plays key roles in the 
localisation of CapZ to the Z-disk through its interaction with Hsc70, protein folding and 
degradation, and in the regulation of apoptosis. Given the indirect role BAG3 plays in Z-
disk and muscle function, its binding partners are excellent candidates for further genes 
that may be mutated in MFM. However, given the fact that most of the identified disease 
causing mutations lie outside a recognised domain in BAG3 there may be many more 
functions for BAG3 that remain to be characterised, perhaps including a direct role in the 
Z-disk. 
8. Conclusion 
The many functions of the MFM proteins, which are themselves just a very small subset of 
the Z-disk associated proteins, highlights the complex and dynamic nature of the Z-disk. 
Whilst a characteristic feature of MFM is dissolution of the myofibril, originating at the Z-
disk, these disorders are not due to simple loss or disruption of structural components in 
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this tensile load bearing structure. This is exemplified by the identification of BAG3, which 
localises to the Z-disk but appears to only have indirect association to it, as an MFM protein. 
Further support comes from analysis of mouse knockouts for the MFM genes, none of which 
have defects in the formation of myofibrils. 
The progressive nature of the disease and the identification of roles for the associated 
proteins in muscle repair and maintenance is more suggestive of a gradual accumulation 
of defects in Z-disk organisation eventually leading to structural failure. An interesting 
finding from mice lacking the long isoforms of ZASP is that they have increased levels  
of the MFM proteins Myotilin, CRYAB, and FLNC as well as the extracellular matrix 
proteins β1D Integrin and the sarcoglycans [189]. Up-regulation of Z-disk components  
is observed in α-Actinin-3 knockout mice in which FLNC, Myotilin, ZASP, and CRYAB 
are up-regulated [249]. Increased levels of FLNC are also detected in patients with 
LGMD or Duchenne muscular dystrophy [213]. This data, together with that previously 
presented, strongly supports the idea that the MFM proteins are up-regulated to protect 
the sarcomere and ECM from damage, whether that damage is caused by muscle 
activity, mutation of muscle proteins, or increases in oxidative, metabolic, and other 
forms of cell stress. Whether this is through a general stress response pathway that up-
regulates the expression of Z-disk associated proteins or through a more specific 
pathway that selectively target proteins based on the nature of the stress remains to be 
determined. 
For more than half of the cases of MFM the causative mutation is not known. As we have 
described there are many binding partners for the known MFM proteins, mutations in 
which may account for some of these cases. Additionally there is evidence from 
experiments with Desmin that mutations in other genes may act as modifiers of disease. 
Far more mutations have been identified in Desmin than in other MFM genes and it may 
be that modifiers will be identified in other subtypes of MFM as larger cohorts are 
analysed. Given the hypothesised role for the MFM proteins in stress response it is 
possible that any mutations that result in cellular stress may modify the presentation of 
MFM perhaps accounting for some of the differences in age of onset. Furthermore, 
differences in stress between cardiac and skeletal tissues may explain the differences in 
symptoms between these tissues, even in individuals with the same mutation. As the 
application of whole genome sequencing to mutation detection in myopathy becomes 
more widespread it may be possible to identify potential modifiers and investigate their 
role in MFM. 
The existing literature on MFM and the MFM associated proteins has identified many 
exciting avenues for investigation. To investigate these areas further animal models, 
modelling specific MFM mutations, are required that would allow for better characterisation 
of pathology and the progression of disease together with a consistent genetic background 
to allow the analysis of potential genetic modifiers. The development of better tools to 
investigate the function of the MFM proteins, together with the identification of further 
MFM genes and modifiers, will allow us to improve our understanding of the many diverse 
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and complex roles of these Z-disk associated proteins and move closer to the development 
of effective therapies for these conditions. 
9. Abbreviations  
ACD domain: -crystallin domain 
AVB: atrioventricular block 
BAG3: Bcl2-related athanogene 3 
CM: cardiomyopathy 
CRYAA: αA-Crystallin 
CRYAB: αB-Crystallin 
DCM: dilated cardiomyopathy 
DRM: Desmin-related myopathy 
ECM: extracellular matrix 
FLNC: Filamin C 
HCM: hypertrophic cardiomyopathy 
IF: intermediate filament 
Ig: immunoglobulin 
LVNCC: left ventricular non-compaction cardiomyopathy 
MA: muscle atrophy 
MFM: myofibrillar myopathy  
MW: muscle weakness 
PGM1: Phosphoglucomutase 1 
PKC: Protein kinase C 
SBM: spheroid body myopathy 
ULF: unit length filament 
UPS: ubiquitin proteasome system 
UTR: untranslated region 
VEFR: ventricular ejection fraction reduction 
ZASP: Z-band alternatively spliced PDZ-motif protein 
WT: wildtype  
ZM: ZASP/Cypher-like motif 
GFAP: Glial fibrillary acidic protein 
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